bi-4SCAR GD2/CD56 / SZGIMI - LARVOL DELTA

GD2/CD56 Bi-specific CAR-T Cell Therapy (clinicaltrials.gov) - P1/2 | N=60 | Terminated | Sponsor: Shenzhen Geno-Immune Medical Institute | Trial completion date: Dec 2030 ➔ Jul 2026 | Recruiting ➔ Terminated | Trial primary completion date: Dec 2029 ➔ Jul 2026

Trial completion date • Trial primary completion date • Trial termination • Oncology • NCAM1

GD2/CD56 Bi-specific CAR-T Cell Therapy (clinicaltrials.gov) - P1/2 | N=60 | Recruiting | Sponsor: Shenzhen Geno-Immune Medical Institute | Trial completion date: Jun 2026 ➔ Dec 2030 | Trial primary completion date: Dec 2025 ➔ Dec 2029

Trial completion date • Trial primary completion date • Oncology • NCAM1

GD2/CD56 Bi-specific CAR-T Cell Therapy (clinicaltrials.gov) - P1/2 | N=60 | Recruiting | Sponsor: Shenzhen Geno-Immune Medical Institute

CAR T-Cell Therapy • New P1/2 trial • Oncology • NCAM1